We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Tandem Diabetes advances insulin therapy with t:slim X2 CGM integrations and the U.S. rollout of Tandem Mobi.
TNDM exited Q4 2025 with $293M in cash and investments, no current debt, and $310M in long-term debt.
TNDM faces intense competition and macro uncertainty; the company reported a $0.6M net loss in Q4.
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce competitive pressure and the adverse impact of macroeconomic challenges.
In the past year, this Zacks Rank #3 (Hold) company’s shares have gained 14.8% against the industry’s 1.7% decline. The S&P 500 composite has risen 26% in the said time frame.
The renowned medical device company has a market capitalization of $1.43 billion. Tandem Diabetes projects a growth rate of 64.7% for 2026 earnings compared with 32.5% for the S&P 500.
Let’s delve deeper.
TNDM’s Key Tailwinds
Impressive Product Innovation Continues: Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. Its flagship t:slim X2 insulin pump software became compatible with the Dexcom G7 and Dexcom G6 continuous glucose monitoring (CGM) systems in 2024.
Following this development, t:slim X2 was approved for sale by Canada Health. Also, the t:slim mobile application is available for Android and iOS users in Canada. t:slim X2 is also compatible with Eli Lilly and the company’s Lyumjev in the European Union and the United States. The t:slim X2 insulin pump became the first pump in the United States to be integrated with both the FreeStyle Libre 2 and FreeStyle Libre 3 Plus CGM sensors from Abbott.
The latest addition to the pump platform portfolio, Tandem Mobi, is helping create a new category of devices for insulin therapy. The company began the U.S. launch of Tandem Mobi in February 2024, followed by its integration with the Dexcom G7 and Dexcom G6 continuous glucose monitoring (CGM) systems. In 2025, Mobi received FDA clearance for its Android version. TNDM also expanded its digital technology solutions with the launch of Tandem Source. The company has accelerated development of Sigi — an ergonomic, rechargeable and detachable patch pump — in San Diego. Its pipeline also includes SteadiSet, an extended-wear infusion set technology.
Stable Solvency: Tandem Diabetes has a solid balance sheet position. It exited the fourth quarter of 2025 with cash and cash equivalents and short-term investments of $293 million. The company didn’t report any current debt during the quarter. Long-term debt during the quarter was $310 million, which remained flat sequentially.
Image Source: Zacks Investment Research
Concerns for TNDM
Tough Competitive Pressure: Tandem Diabetes operates in a highly competitive environment, dominated by firms ranging from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit the company’s ability to switch to strategies like price increases. These significant changes within the industry may affect TNDM’s business and operating results.
Macroeconomic Headwinds Persist: Uncertainties related to the current global economic and political environment may make it challenging for TNDM to accurately predict demand for its products. These conditions could also increase the company’s expenses and negatively impact its overall financial performance. In the fourth quarter, TNDM reported a net loss of $0.6 million.
Estimate Trend
The Zacks Consensus Estimate for 2026 loss per share has narrowed 8 cents to 91 cents in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.08 billion, which suggests an increase of 6% from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Edwards Lifesciences (EW - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 19.5% against the industry’s 3.7% decline over the past year.
Intuitive Surgical, sporting a Zacks Rank #1, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have risen 1.5% against the industry’s 3.7% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.6% against the industry’s -0.7% yield. Shares of the company have climbed 23.2% against the industry’s 3.7% decline. EW’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 5.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
Key Takeaways
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce competitive pressure and the adverse impact of macroeconomic challenges.
In the past year, this Zacks Rank #3 (Hold) company’s shares have gained 14.8% against the industry’s 1.7% decline. The S&P 500 composite has risen 26% in the said time frame.
The renowned medical device company has a market capitalization of $1.43 billion. Tandem Diabetes projects a growth rate of 64.7% for 2026 earnings compared with 32.5% for the S&P 500.
Let’s delve deeper.
TNDM’s Key Tailwinds
Impressive Product Innovation Continues: Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. Its flagship t:slim X2 insulin pump software became compatible with the Dexcom G7 and Dexcom G6 continuous glucose monitoring (CGM) systems in 2024.
Following this development, t:slim X2 was approved for sale by Canada Health. Also, the t:slim mobile application is available for Android and iOS users in Canada. t:slim X2 is also compatible with Eli Lilly and the company’s Lyumjev in the European Union and the United States. The t:slim X2 insulin pump became the first pump in the United States to be integrated with both the FreeStyle Libre 2 and FreeStyle Libre 3 Plus CGM sensors from Abbott.
The latest addition to the pump platform portfolio, Tandem Mobi, is helping create a new category of devices for insulin therapy. The company began the U.S. launch of Tandem Mobi in February 2024, followed by its integration with the Dexcom G7 and Dexcom G6 continuous glucose monitoring (CGM) systems. In 2025, Mobi received FDA clearance for its Android version. TNDM also expanded its digital technology solutions with the launch of Tandem Source. The company has accelerated development of Sigi — an ergonomic, rechargeable and detachable patch pump — in San Diego. Its pipeline also includes SteadiSet, an extended-wear infusion set technology.
Stable Solvency: Tandem Diabetes has a solid balance sheet position. It exited the fourth quarter of 2025 with cash and cash equivalents and short-term investments of $293 million. The company didn’t report any current debt during the quarter. Long-term debt during the quarter was $310 million, which remained flat sequentially.
Image Source: Zacks Investment Research
Concerns for TNDM
Tough Competitive Pressure: Tandem Diabetes operates in a highly competitive environment, dominated by firms ranging from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit the company’s ability to switch to strategies like price increases. These significant changes within the industry may affect TNDM’s business and operating results.
Macroeconomic Headwinds Persist: Uncertainties related to the current global economic and political environment may make it challenging for TNDM to accurately predict demand for its products. These conditions could also increase the company’s expenses and negatively impact its overall financial performance. In the fourth quarter, TNDM reported a net loss of $0.6 million.
Estimate Trend
The Zacks Consensus Estimate for 2026 loss per share has narrowed 8 cents to 91 cents in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.08 billion, which suggests an increase of 6% from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Edwards Lifesciences (EW - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 19.5% against the industry’s 3.7% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical, sporting a Zacks Rank #1, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have risen 1.5% against the industry’s 3.7% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.6% against the industry’s -0.7% yield. Shares of the company have climbed 23.2% against the industry’s 3.7% decline. EW’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 5.5%.